title: [Comparative study of HR HPV E6/E7 mRNA and HR-HPV DNA in cervical cancer screening].
abstract: OBJECTIVE
  To determine the performance of HR-HPV E6/E7 massager RNA (mRNA) test for detecting high-grade cervical intraepithelial neoplasia in cervical cancer screening and compare the clinical performance of HR-HPV E6/E7 mRNA test with HC-2 and Cervista HPV DNA tests for cross-sectional positivity in women with and without cervical neoplasia.
  
  
  METHODS
  A total of 172 women underwent cytology, HR-HPV DNA test, HR-HPV E6/7 mRNA test, colposcopy and biopsy. We compared the clinical performance of HR-HPV E6/E7 mRNA test with Hybrid Capture 2 DNA test (HC-2) and Cervista HR-HPV DNA test on the cervical brush specimens during colposcopy and routine screening. The samples were histologically confirmed high-grade cervical intraepithelial neoplasia (CIN II) or worse (CIN II+) as an endpoint.
  
  
  RESULTS
  HR-HPV E6/E7 mRNA positive rate was 37.9% in NILM, 67.9% in ASCUS and LSIL, 88.5% in ASC-H+. HR-HPV E6/E7 mRNA positive rate was 38.6% in CIN I, 77.4% in CIN II-3 and 92.5% in SCC. HR-HPV E6/E7 mRNA test showed a higher specificity than HC-2 and Cervista HPV DNA tests for high-grade lesions (61.4%, 54.3%, 55.7%, respectively, P < 0.05) and also a higher positive predictive value (75.9%, 74.8%, 74.6% respectively). Among three tests, HR-HPV E6/E7 mRNA had the largest area of ROC curve and the best diagnostic value.
  
  
  CONCLUSIONS
  HR-HPV E6/E7 mRNA test has a performance more specific for detecting CIN II+ with the same sensitivity as HC-2 and Cervista HPV DNA tests. And it may serve as a more specific test for predicting the risk of progression and offer a viable tool for triage during cervical cancer screening.
authors.affiliation: Chinese PLA General Hospital & Chinese PLA Medical School, Beijing 100853, China.
authors.forename: Xuye
authors.initials: X
authors.lastname: Zhao
authors.forename: Yong
authors.initials: Y
authors.lastname: Cui
authors.forename: Shufang
authors.initials: S
authors.lastname: Jiang
authors.forename: Yuanguang
authors.initials: Y
authors.lastname: Meng
authors.forename: Aijun
authors.initials: A
authors.lastname: Liu
authors.forename: Linping
authors.initials: L
authors.lastname: Wei
authors.forename: Tongyu
authors.initials: T
authors.lastname: Liu
authors.forename: Haiqiong
authors.initials: H
authors.lastname: Han
authors.forename: Xiaosu
authors.initials: X
authors.lastname: Liu
authors.forename: Fuhong
authors.initials: F
authors.lastname: Liu
authors.affiliation: Email: zlxy79680@126.com.
authors.forename: Yali
authors.initials: Y
authors.lastname: Li
mesh_terms: D001706:Biopsy; D003127:Colposcopy; D003430:Cross-Sectional Studies; D004279:DNA, Viral; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D009856:Oncogene Proteins, Viral; D027383:Papillomaviridae; D011247:Pregnancy; D012333:RNA, Messenger; D012367:RNA, Viral; D002578:Uterine Cervical Dysplasia; D002583:Uterine Cervical Neoplasms
chemical_list: D004279:DNA, Viral; D009856:Oncogene Proteins, Viral; D012333:RNA, Messenger; D012367:RNA, Viral